SATO, T., .SUGA, M., KUDO, H., WAGA, T., OGASAWARA, M. and USUBUCHI , I. Cross-Immunity among Allogeneic Tumors in Rats Immunized with GammaIrradiated Ascites Tumors. Tohoku J. exp. Med., 1980, 131 (4) , 387-391 -Non-inbred rats of the Gifu strain were intraperitoneally challenged with Hirosaki sarcoma (tetraploid type, 105 cells) after repeated immunization with gammairradiated (13,000 rads 60Co) allogeneic non-viral tumors of ascites type (tetraploid or diploid type of Hirosaki sarcoma, Usubuchi sarcoma or AH130). In rats immunized not only with the same tumor as the immunizing tumor but also with a different tumor, the growth of the challenge tumor was markedly inhibited as compared with the control in non-immunized rats.
It is considered that these tumors retained common antigen(s) by the resistance to irradiation because of their form of ascites tumor. The marked cross-immunity in rats immunized with AH130 may be explained by the fact that gamma-irradiated AH130 cells were alive longer in the peritoneal cavity than other tumors on account of its high resistance to irradiation. -cross-immunity; allogeneic tumors; immunization with irradiated ascites tumors It has been an almost universal opinion that cross-immunity exists among virusinduced tumors, but not among chemically induced tumors which have individu ally specific tumor antigen(s) (Klein et al. 1960 ). However, the establishment of cross-immunity among chemically induced tumors has been recently reported by not a few investigators (Jamasbi and In the present study using allogeneic non-viral tumors of ascites type, we attempted to find out whether or not cross-immunity is observed among these tumors in rats immunized with gamma-irradiated tumors.
MATERIALS AND METHODS

Animals
Non-inbred rats of the Gifu strain of both sexes, weighing from 120 to 150 g, were used. They were kept on Oriental MF (Oriental Yeast Ind. Co.) and watered freely.
Tumors
Hirosaki sarcoma (diploid and tetraploid type) (Usubuchi and Abe 1956 ). This tumor has been maintained in the form of a transplantable ascites tumor converted from a spontaneous lymphosarcoma of the cervical lymph node in a non-inbred rat of the Gifu strain in this laboratory.
The original tumor was diploid. The tetraploid type was separated during serial intraperitoneal transplantation.
When 107 cells of both types of tumors are transplanted intraperitoneally, all of the rats die after a mean survival time of 7 days. Usubuchi sarcoma (Usubuchi 1955 ). Usubuchi sarcoma has been maintained in the form of a transplantable ascites tumor converted from a subcutaneous MCA-induced sarcoma in a non-inbred rat of the Gifu strain in this laboratory.
Intraperitoneal inocula tion of 107 cells of this tumor kills all of the rats after a mean survival time of 10 days.
AH130 (Yoshida 1957 ). This transplantable ascites tumor was supplied by Dr. Satoh, The Sasaki Institute, Tokyo. AH130 was transformed from a 4-diethylaminoazobenzene-induced hepatoma into an ascites form in a non-inbred rat in the same institute. After a mean survival time of 9 to 14 days, all of the rats are killed by intraperitoneal inoculation of 107 cells.
Survival time of gamma-irradiated tumor cells
In order to observe the effect of gamma-irradiation (13,000 rads 60Co) on ascites tumor cells, 107 gamma-irradiated cells of each tumor were transplanted into the peritoneal cavity of rats. The examination of the tumor-ascites was carried out daily and the survival time was determined by the time up to the extinguishment of tumor cells. respectively. The time of AH130 was remarkably longer than that of the other tumors (Table 1) . Challenges of Hirosaki sarcoma (tetraploid type) into the peritoneal cavity of rats immunized with gamma-irradiated allogeneic tumor
The inhibition of the growth of the tetraploid type of Hirosaki sarcoma in rats immunized with one of the tumors different from the immunizing tumor, such as the diploid type of Hirosaki sarcoma, Usubuchi sarcoma or AH130, was observed as well as in rats immunized with the tetraploid type of Hirosaki sarcoma which was the same tumor as the immunizing tumor.
In rats immunized with AH130, the inhibition of the growth was markedly observed (Table 2) . 
DISCUSSION
The data obtained in the present study show clearly cross-immunity among non-viral allogeneic tumors by immunization with gamma-irradiated ascites tumors (Table 2 ). In our previous work on cross-immunity between mammary carcinomas in C3H/He mice by using gamma-irradiated syngeneic tumor, it was difficult to exclude completely the participation of the virus (Kudo et al. 1980 ). Non-viral tumors in rats being used in this study, no participation of the virus is considered. Usubuchi et al. (1972) reported previously that cross-immunity was demon strated among all of 5 allogeneic rat tumors employed without exception and that the cross-immunity can be explained, therefore, only by the common antigens among allogeneic tumors and not by the interaction of the histocompatibility antigens.
The findings in this study showing marked cross-immunity among all of 4 allogeneic tumors definitely confirmed that conclusion.
How can it be reasonably explained that cross-immunity between allogeneic ascites tumors was remarkably shown by immunization with gamma-irradiated ascites tumors ? In spite of a high dose of gamma-irradiation (13,000 rads 60Co), the tumor cells transplanted into the peritoneal cavity were alive for 1.4 to 4.8 days showing degenerative changes (Table 1) . From this observation, it seems that the ascites type of tumor is more resistant to irradiation than the solid type and, so, causes cross-immunity by the remaining common antigen(s) during the survival time.
The dominant cross-immunity observed in rats pretreated with AH130 is considered to be the expression of a high resistance of AH130 to irradiation.
On the other hand, in a study employing the solid type of tumors, it was difficult to demonstrate the common antigenicity in animals pretreated with gammairradiated solid tumors (Usubuchi et al. 1975) . As compared with the present study, the solid tumors seem to have a low resistance to irradiation, and, therefore, their common antigenicity may be destroyed easily.
Based on the results obtained in this laboratory, how shall we make practical use of the cross-immunity among allogeneic tumors ? Some attempts at immunotherapy on the growth of autochthonous MCA-induced sarcomas in rats by using allogeneic tumors were carried out in this laboratory (Usubuchi et al. 1976 ; Kudo et al. 1979 ). In immunotherapy of human cancer, it is not easy to get the ascites type of human cancer which has a high resistance to irradiation.
However, by immunization first with irradiated solid tumors, it may then be possible to safely use viable cells of the same tumor which induces cross-immunity to the primary autochthonous tumor.
